

Table I Clinical and pathological features

Variable	Study Group	All	"p"	Recurrent	Non-Recurrent	"p"	
#Patients		52	393	8	13		
Age	Median	58.5	61	0.32	58.5	60.0	0.74
	Range	47-72	40-79		51-72	47-72	
PSA	Median	6.3	6.7	0.62	6.8	6.3	0.64
	Range	1.0–27.8	0.7–46.0		5.0-24.3	3.6-18.0	
Gleason Score (Clinical)	2-6	19(37%)	190(51%)	0.10	2(25%)	6(46%)	0.45
	7	29(56%)	146(39%)		5(63%)	6(46%)	
	8–10	4(8%)	34(9%)		1(12%)	1(8%)	
	Unknown		23				
Gleason Score (Sample)	2-6	24(46%)		0.46*	1(12%)	7(54%)	0.01
	7	22(42%)			3(38%)	6(46%)	
	8–10	6(12%)			4(50%)	0	
Clinical Stage	T1-T2a	38(88%)	285(79%)	0.10	5(100%)	10(91%)	1.00
	T2b	5(12%)	24(7%)		0	9(9%)	
	≥T2c	0	50(14%)		0	0	
	Unknown	9	34		3	2	
Pathologic Stage	T2a	7(13%)	49(15%)	0.15	1(13%)	2(15%)	0.90
	T2b	25(48%)	189(58%)		4(50%)	5(38%)	
	T3a	16(31%)	74(23%)		2(25%)	4(31%)	
	T3b	4(8%)	12(4%)		1(13%)	2(15%)	
	T4a	0	2(1%)		0	0	
Unknown		53					
Gland Vol.	Median	51.75	53.0	0.89	67.5	50.0	0.15
	Range	35-191	18-191		35.5-191	35-169	
Ext.Cap.	No	32(62%)	239(73%)	0.10	5(63%)	7(54%)	1.00
	Yes	20(38%)	88(27%)		3(37%)	6(46%)	
	Unknown		66				
SVInv.	No	49(94%)	315(96%)	0.44	7(88%)	12(92%)	1.00
	Yes	3(6%)	12(4%)		1(12%)	1(8%)	
	Unknown		66				
Pos.Mar.	No	39(75%)	283(76%)	0.86	5(62%)	7(54%)	1.00
	Yes	13(25%)	89(24%)		3(38%)	6(46%)	
	Unknown		21				

PSA serum prostate specific antigen, Vol. Volume, SV Inv. seminal vesicle invasion  
 Ext Cap. Extension through capsule, Pos. Margin positive surgical resection margin  
 Gleason Score (Clinical) indicates the Gleason Score recorded from the radical prostatectomy specimen. Gleason Score (Sample) indicates the Gleason Score of the frozen sections from the tumor specimens used in RNA preparation. \*p value resulting from the comparison of the Gleason Score (Sample) of the 52 tumors to the Gleason Score (Clinical) from the entire population.